source
- Fulcrum exploring a potential sale after FDA sidelined its sickle cell drugFulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.BioPharma Dive · 1mo ago↗ source
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto settingAbivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The ReadoutSTAT · 1mo ago↗ source
- STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and moreLilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaksSTAT · 1mo ago↗ source